Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies such as panitumumab and cetuximab as single agents showed an activity in Kras wild-type colorectal cancer but presented limited benefits (1–2 months) (35, 36). The gene discussed is KRAS; the disease is colorectal cancer.